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Objectives: Evaluation of Fluorescent in situ hybridization (FISH) as a tool for rapid aneuploidy screening (RAS) of
high risk pregnancies, before its approval in the national antenatal screening and genetic diagnosis program in
Egypt.
Methods: The cytogenetic data of prenatal specimens, and results of FISH of 100 patients performed between,
January 2009 and December 2009, at the Medical Genetics Center (MGC) laboratory were retrieved and reviewed.
AneuVysion Assay kit was used for detection of 13, 21, X, Y, 18 aneuploidies.
Results: Maternal age varied from 21 to 44 years (mean was 35.6 year). Ninety percent of pregnancies had normal
chromosomes and 10% of the cases had numerical chromosomal abnormalities. Trisomy 21 was the most frequent
chromosomal disorder across all indications (5%), followed by Turner syndrome (2%), trisomy 18 (2%), and trisomy
13 (1%). When comparing the FISH data with karyotype results for chromosomes 13, 18, 21, X, and Y in the 83
individual tested, no false positive or negative results were detected by the FISH assay. The result obtained by FISH
and the banding cytogenetic were in complete accordance.
Conclusion: This study supports the integration of amniotic fluid (AF) FISH as a RAS test, in to routine antenatal
practice for identification of chromosome aneuploidies. There are trends towards delayed childbearing and most
cases of Down Syndrome (DS) are currently detected post-nataly in the Egyptian population. Consequently, the live
birth prevalence of DS has increased, which might lead to a serious negative public health effects.
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Over the last 30 years, U.S. Agency for International
Development (USAID) and Egypt’s primary focus was on
assisting the Ministry of Health and Population (MOHP)
to increase the availability of family planning (FP) and
public health services. The Egyptian FP and reproductive
health (RH) program has achieved considerable success
over the last three decades, preventing millions of
infants and child deaths and high risk-births in Egypt
and saving tens of thousands of mothers’ lives. Before
the program began in the 1970 the country had hardly
any FP services or products, maternal and infant* Correspondence: elsayed276@yahoo.com
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in any medium, provided the original work is pmortality rates were high, and population growth was
straining the country resources (Adel-Tawab et al. 2008).
Impressive improvements in maternal health care are
saving women’s life throughout Egypt. The changes
were accomplished in less than 8 years (1993–2000) by
employing a systemic approach to addressing avoidable
causes of death. An essential package of Maternal and
Child Health (MCH) services and standards of antenatal
care (ANC) and postnatal care, delivery and obstetric
care, neonatal care, and preventive child death was ap-
plied in targeted governorates reducing suffering and
increasing lives saved. Egypt is now on track to achieve
Millennium development Goal (MDG) 5 of improving
maternal health. The target aims at reducing maternal
mortality rate (MMR) by three-quarters between 1990
and 2015 (Cobb et al. 1993).an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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for, monitoring the progress of pregnancy and regularly
assessing maternal and fetus well-being routinely for all
pregnant women. At least four visits are recommended
and should cover detection of problems complicating
pregnancy (e.g., anemia, hypertensive disorders, bleed-
ing, mal-presentations, and multiple pregnancies); pre-
ventive health care interventions, such as tetanus toxoid
immunization, and iron, folate and iodine supplements
(Chao et al. 2005).
Although there has been an improvement in ANC in
Egypt, there has not been enough focus on antenatal
screening to pregnant women for fetuses with chromo-
somal disorders like DS and other rare disorders like tri-
somy 18 and neural tube defects. Prenatal screening is still
inaccessible to most families and almost all cases of DS
are diagnosed post-natal (El-Sobky and Elsayed 2004).
Prenatal diagnosis for DS has made considerable pro-
gress in the past twenty years. In particular, techniques
using maternal serum and ultrasonography markers
have provided non-invasive antenatal screening tests for
DS. This has been especially important for younger
women who are at lower risk of DS, and hence usually
not candidates for invasive diagnostic procedures, but
who nevertheless often account for the majority of DS
cases due to the size of their population (Wald et al.
1999; Nicolaides et al. 2002).
Along with technical progress in antenatal screening,
public policies on screening have been adopted in several
European countries. The majority of countries have moved
from solely offering older mothers a diagnostic test (chori-
onic villous sampling or amniocentesis) to having some
form of DS screening in place, with over half having
country-wide policy or recommendation for first or sec-
ond trimester screening (Wellesley et al. 2002).
The policy and practice of prenatal screening for
chromosomal anomalies is changing rapidly. New devel-
opments in screening methods have increased the num-
ber of options for patients. Screening options in the first
trimester include nuchal translucency (NT) testing in
combination with measurement of pregnancy-associated
plasma protein A (PAPP-A) and human chorionic go-
nadotropin (hCG). Screening options in the second
trimester include serum screening using triple (hCG,
maternal serum alpha fetoprotein (AFP), unconjugated
estradiol) or quadruple screening (hCG, inhibin A, ma-
ternal serum AFP, unconjugated estradiol), and ultrason-
ography (Boyd et al. 2008).
Having a screening policy in place had a measurable
impact on prenatal detection rates for DS, the registry
areas in countries offering primarily first-trimester
screening had significantly higher detection rate than
those using a mixed first or second trimester screening
policy; those with some screening but no national policyin place were significantly less likely to detect a DS case
prenatally (Anderson and Brown 2009).
After a positive prenatal screening test, women are
usually offered foetal karyotyping, which is considered
the gold standard to confirm the presence or absence of
chromosomal abnormality by counting the number of
chromosomes and looking for structural abnormality
(Gekas et al. 2011).
Karyotyping involves the acquisition of metaphase chro-
mosomes through a period of cell culture that may take
anywhere between 7 and 14 days. Despite increasingly
shorter prenatal result turn-around times due to the wider
adoption of the in-situ coverslip technique and improved
culture media, patients remain anxious while waiting for
the1 to 2 weeks it takes for an AF or chorionic villous
sample (CVS) karyotype result (Lim et al. 2010).
The most frequent foetal chromosomal abnormalities
involve the autosomes 21, 18, 13, and sex chromosomes
X and Y. Aneuploidy or alterations in copy number of
these chromosomes, including trisomy 21 (Down syn-
drome), trisomy 18 (Edwards’ syndrome), trisomy 13
(Patau’s syndrome), 45, X (Turner’s syndrome), and 47,
XXY (Klinefelter’s syndrome) account for 80% of clinic-
ally significant chromosomal abnormalities diagnosed in
the prenatal period (Leung et al. 2008).
Consequently, RAS tests such as (FISH) and quantitative
fluorescence-polymerase chain reaction (QF-PCR) assays
to detect numerical abnormalities of chromosomes 13, 18,
21, X and Y have become increasingly popular adjunct
tests. Unlike karyotyping, these test results are typically
available within 24 hours thereby alleviating much of the
anxiety from these patients. This has been one of the main
reasons for the introduction of molecular (cytogenetic)
methods for prenatal diagnosis of the most common
chromosome disorders (Liehr and Ziegler 2005).
Currently, there is no national prenatal screening pro-
gram in Egypt; some pregnant mothers obtain screening
as a part of their obstetric care in the private sector on a
fee –for- service basis.
The objective of this study is to evaluate the usefulness
and limitations of FISH as a tool in RAS for high risk
aneuploidies (13, 21, 18, X, Y) before its approval in




From January 2009 to December 2009, 437 pregnant
women were referred to the MGC for prenatal diagnosis.
Our policy is to provide all women with interphase FISH
assay within 48 hours followed by cytogenetic analysis. If
rapid analysis by FISH was considered as a replacement
for standard karyotyping, the indication for prenatal
diagnosis should be either positive screening test for DS
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different methods of prenatal diagnosis are discussed,
and the final decision is left to the parents.
In this study, interphase FISH analysis and the cytogen-
etic data and of 100 consecutive patients who agreed to
have FISH and cytogenetic analysis in the study period
were retrieved and reviewed. Seventeen patients had FISH
analysis only due to insufficient sampling.
The clinical indications of prenatal diagnosis in this
study included, abnormal maternal serum screening
(MSS) if the risk reached or exceeded 1 in 300 for trisomy
21 or 1 in 150 for trisomy 13/ trisomy 18, abnormal ultra-
sound (AU), AMA (≥35 years), family history of genetic/
chromosomal disorders (previous DS), and prenatal anx-
iety. Amniocentesis was performed at around 16 weeks of
gestation and usually 20 ml of fluid was collected. CVS
samples were performed at 12 weeks of gestation trans-
abdominally and villi were processed for direct harvesting,
culture and FISH.
Fluorescence in-situ hybridization
Fluorescence in-situ hybridization probes
The FISH assay employed the AneuVysion Assay Kit
(Abbot Molecular, US) consisting of three α-satellite DNA
probes for chromosomes X, Y, and 18 (cep X, cep Y, cep
18) and two locus specific probes (LSI) for 13q14 (LSI 13)
and 21q22.13-22.2 (LSI 21). The three centromeric probes
and the two locus-specific probes are applied to the sam-
ple in two different hybridizations slides.
Cytogenetic analysis
Amniocytes were cultured and Q banding was performed
for most of the cases. Routine evaluation of each case
involved analysis of 20 random metaphase spread from
two independent cultures. Four metaphase spreads were
photographed for karyotyping using imaging system.
When mosaicism was suspected more than 50 meta-
phase spreads were analyzed. Karyotypes were described
according to the International System for Human Cyto-
genetic Nomenclature (2005) (ISCN2005).
Preparation of uncultured amniocytes
About 2 to 5 ml of AF were centrifuged (1000 rpm, 5 min)
and the cell pellet was re-suspended in 3 ml trypsin/EDTA
and incubated for 15 min at 37°C. After centrifugation, the
pellet was suspended in 5 ml 0.075 KCL and incubated at
37°C for 20 min. After addition of 2 ml Carnoy fixative
[methanol: acetic acid (3:1)], centrifugation, re-suspension,
and incubation at -20°C for 5 min in 3 ml carnoy fixative.
The supernatant was discarded and the cells were diluted
in 200 μl of the remaining supernatant. The cells of each
sample were smeared on two different slides, one slide for
hybridization with probes LSI 13 (green) and 21 (red), andthe other slide for hybridization with probes CEP 18
(blue), CEP X (green), and CEP Y (red).
For hybridization, the slides were incubated with pepsin
in 0.01 mol/L HCL at 37°C for 8 min. Then the slides were
washed with 2× SCC for 2 min, and dehydrated with etha-
nol at 70%, 85%, and 100% in sequence, and air-dried.
Each probe mixture was individually dropped on one slide,
covered by a cover glass and sealed with rubber cement.
Co-denaturation and hybridization were carried out in a
HYBrite system (Abbott) overnight. The next day, the
slides were washed and prepared for analysis.
Analytical criteria
For each probe, at least fifty nuclei were evaluated. Nuclei
free from any attached cytoplasm or cellular membrane
showing 1, 2, 3, or 4 signals were selected for scoring.
Only those signals, which were well embedded in the nu-
cleus, were included for scoring. Clumped or overlapping
nuclei and nuclei with high background intensity or low
signal intensity were not scored. Patchy and diffused
signals were included in the evaluation only if they were
well separated. Split-spots (i.e. signals in a paired ar-
rangement) were scored as one signal only if the
distance between the signals was less than the width of
one of these signals; otherwise they were observed as
two signals. On the basis of FISH scoring results, the
samples were considered to be informative normal and
abnormal (however final diagnosis was made only on
the basis of karyotyping). Informative normal/disomic
samples were defined as samples in which ≥ 80% of all
nuclei from each autosomal hybridizations demon-
strated two signals and ≥ 80% of all nuclei from the sex
chromosomal hybridization demonstrated the XX or
XY signal pattern. Informative abnormal specimen were
defined as those in which ≥ 70% of the nuclei spreads
hybridized with an autosomal probe demonstrated 3
signals or ≥ 70% of the nuclei spreads hybridized with
the X- and Y-probes demonstrated signal patterns other
than XX- and XY-signals.
As long as not more than 7-10% of the studied cells
were present with three specific signals, no trisomy of
the corresponding chromosomal region is suspected and
a normal report (disomic) is issued.
Informative mosaic samples were defined as those in
which a value of > 20% of nuclei had a variation in
signal number from the majority or showed a signal
pattern other than the normal disomic autosomal or
normal sex chromosomal (XX and XY) signals. At be-
tween 7-10% and 20%, the evaluation was regarded as
unclear result and the number of cells evaluated was
increased to 100 or more nuclei to come to a final deci-
sion. If the above criteria were not met the result were
reported as uninformative (Liehr and Ziegler 2005;
Jobanputra et al. 2002).
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fetuses, maternal cell contamination can be detected
but in fluid of female fetuses, such contamination
could not be detected. Therefore, the results for normal
female fetuses were interpreted carefully using lower
cut-off values.
Results
A total number of 100 consecutive prenatal samples were
analyzed among, 437 amniocentesis in the MGC from
January 2009 to December 2009. Maternal age varied from
21 to 44 years (mean was 35.6 year) and gestational age at
the time of the procedure varied from 12 to 27 weeks
(mean age was 16 + 4 weeks).
From a total number of 100 pregnant women, 17 had
only prenatal FISH assay and 83 had conventional karyo-
type and prenatal FISH analysis. The FISH analysis
showed that 90% of pregnancies had normal chromo-
somes and 10% of the cases had numerical chromosomal
abnormalities.
Chromosome anomalies identified by the FISH tech-
nique were 8 cases (8%) of autosomal aneuploidies and
two cases (2%) of gonosomal aneuploidies. Trisomy 21
was the most frequent chromosomal disorder across all
indications (5%), followed by Turner syndrome (2%),
trisomy 18 (2%), and trisomy 13 (1%).
When comparing the FISH data with karyotype re-
sults for chromosomes 13, 18, 21, X, and Y in the 83
individual tested, no false positive or negative results
were detected by the FISH assay. The result obtained
by rapid aneuploidy test and the banding cytogenetic
were in complete accordance.
The clinical indications for prenatal genetic diagnosis
included, abnormal MSS (50%), AU findings (17%),
(AMA) (16%), family history of genetic/chromosomal
disorder (previous DS) (8%), and prenatal anxiety (9%).
In cases where there were multiple indications, priority
of indications was assigned as follows: AU, MSS, and
AMA. The majority of abnormalities identified by pre-
natal studies were due to MSS (4%), UA (4%), and AMA
(2%), Table 1.Table 1 The analysis of the recommendations for amniocente
chromosome abnormalities
Indications Number of patients Tris
Maternal serum screening positive 50 2
Abnormal ultrasoungraphic findings (US) 17 1
Advanced maternal age (≥ 35 years) 16 2
Family history of genetic/chromosomal disorder 8 0
Parental anxiety 9 0
Total 100 5All FISH studies were completed and reported within
24–72 hours, while the time varied from 2–3 weeks for
conventional karyotyping. FISH results were reported to
be significantly faster than those for karyotyping. However,
5% of cases were problematic due to inadequate cell num-
ber, maternal cell contamination or hybridization failure.
In these cases an adequate FISH result was obtained by
repeating FISH on the same slide or analyzing floating
amnion cells from supernatant in cell culture flaks.
Discussion
Amniocentesis is the most common invasive prenatal pro-
cedure for detection of fetal chromosomal abnormalities.
In this study, abnormal MSS was the most common
indication. This finding was similar to the results of previ-
ous studies (Choi et al. 2005; Jang et al. 2007; Han et al.
2008). In contrast, recent studies performed in Egypt
showed that previous history of an abnormal child was the
most common indication for amniocentesis (Helmy et al.
2009; Atef et al. 2011). This difference reflects the in-
creased awareness of our patients about the importance of
prenatal serum screening tests. It should be considered
that MGC is a private laboratory, and most of our patients
come from high social class families, when compared to
the previous studies performed at governmental hospitals
where free or minimum charge prenatal diagnosis is pro-
vided for high risk group only.
Previous reports on prenatal diagnosis of amniocentesis,
consisting of various numbers of cases, have revealed
that the incidence of chromosomal abnormalities ranges
from 1% and 6.7% (Tseng et al. 2006; Han et al. 2008).
This study found 10% of 100 cases had chromosomal
abnormities, which was similar to the data from Egyptian
study by Shawky et al. 2009.
In this study, DS was the most common abnormality
detected (5%) by prenatal diagnosis and at the same year
2009, 429 (8.7%) live- birth DS were diagnosed postna-
tally in the MGC. Prenatal diagnosis of DS is not avail-
able for most of pregnant women in Egypt and the
National DS cytogenetic register is not yet developed to
compare our results. However, there are several reportssis that conducted to the discovery of the numerical
omy 21 Trisomy 18 Trisomy 13 Monosomy X Total aneuploidy
N (%)
1 0 1 4/50 (8)
1 1 1 4/17 (23.5)
0 0 0 2/16 (12.5)
0 0 0 0
0 0 0
2 1 2 10
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the world, with respect to ethnicity and maternal age
(Warburton et al. 2004; Lamb et al. 2005). An earlier
study in Egypt have reported the incidence of DS as, 1
per 700 births and 98.4% of cases were diagnosed post-
natal and only 1.56% were detected prenatally with an
estimated risk of 2285 DS births annually (El-Sobky and
Elsayed 2004). Our result suggests an increased aware-
ness of our group of patients about the importance of
antenatal screening for DS. On the other hand, the
MOHP in Egypt did not adopt proper antenatal screen-
ing as a public policy till today (El-Gilany et al. 2011;
Shalaby 2011).
There are two factors known to influence the number of
live births with DS- the underlying incidence of the syn-
drome to the distribution of maternal age, and the number
of pregnancies that are detected antenatal and subse-
quently terminated (Shalaby 2011; Morris and Alberman
2009). In this work, the mean age of mothers was ad-
vanced (35.6 years) when compared to the mean maternal
age in Egypt (21.9 ± 3.45 years, 2008), (Finaly et al. 2011).
Traditionally, screening for trisomy 21 was based on
maternal age and biochemical testing of second trimes-
ter (14–18 weeks) maternal serum AFP (Snijders et al.
1998). However, it can now be provided effectively by a
combination of the ultrasonography measurement of
fetal NT thickness, absence/presence of nasal bone (NB)
in conjunction with biochemical testing for PAPP-A and
hCG at 11 weeks to 13 weeks and six days (13 + 6 weeks)
of gestation. The detection rate of these combined
methods is about 85-90% in regard to trisomy 21 and
18, for a false positive rate of 5% (Agnieszka et al. 2007).
In previous studies (El-Sobky 2007; Tseng et al. 2006;
Yang et al. 1999), the AU findings showed the highest
detection rate for chromosomal abnormalities in pre-
natal diagnosis. In the present study, of the 17 cases with
AU findings, 4 cases resulted in chromosomal abnormal-
ities, which showed the highest positive predictive value
(23%) among the indications. Nowadays, highly sensitive
ultrasonic technology can detect fetal anomalies which
eventually necessitate amniocentesis.
In this study, (90%) of amniocentesis performed for
patients showed normal result. For this large group of
parents, RAS using FISH excluded the possibility of
foetal DS and relieved anxiety within 1–2 days. However,
the final and conclusive result was not available until a
full karyotype was obtained in the week following the
FISH finding, in which abnormalities not detectable by
FISH was unveiled.
Currently, most prenatal diagnosis units offer either
traditional karyotyping only or RAS in addition to karyo-
typing. If cost is not an issue, the latter appears ideal.
However in publicly funded system, money spent in one
area means deprivation in another.There is an ongoing debate surrounding whether RAS
should be employed as an adjunct to karyotyping or
whether it could be used as a stand-alone test in selected
group of women (Leung et al. 2003; Caine 2005; Leung
2005; Bui 2007). The controversy is due to the residual
probability of a chromosome abnormality (both balanced
and unbalanced) when RAS demonstrates a normal result.
In this work, the result obtained by RAS for common
aneuploidies and the banding cytogenetic were in
complete accordance with no false positive or false nega-
tive results. Similar results were obtained by (Pergamnet
et al. 2000; Lim et al. 2002; Settin et al. 2007; Neagos
et al. 2011). The relatively small number of cells needed
for diagnosis (practically 50), gave a much better option to
be more selective in cell quality and was a major factor in
the efficiency and accuracy of the tests.
Although RAS using FISH is highly sensitive and
specific method in the detection of aneuploidy, one of
the disadvantages of FISH is that maternal and fetal XX
cells per se are indistinguishable by FISH, rendering
maternal cell contamination undetectable from female
fetuses. However, maternal cell contamination is readily
detectable with male fetuses, as a mixture for XX and
XY cells are seen. In contrast to the situation of FISH,
maternal cell contamination is readily detected by careful
comparison with profiles from maternal blood sample
in QF-PCR amplification of STR (short tandem repeats)
(Bui 2007; Hulten et al. 2003). For safety, we and many
laboratories discard any heavily contaminated samples
with respect to RAS.
In contrast to the RAS, the array-based comparative
genomic hybridization (a CGH) is a comprehensive, high
resolution, genome-wide screening strategy for obtaining
DNA copy number information in a single measurement
which can be rapid and less laborious than karyotyping
as it is readily amenable to automation. While currently
high costs of the technology need to be addressed before
it can be used in prenatal diagnosis, it is likely to be-
come an important tool with the potential of replacing
karyotyping in the future (Bui 2007).
The feasibility of the RAS stand-alone approach de-
pends on the indication for the invasive prenatal test.
With the presence of major ultrasound-detected foetal
anomalies, traditional karyotyping should be performed
to look for structural chromosomal abnormalities apart
from aneuploidies. The RAS stand-alone approach is
best when the invasive prenatal test is performed for an
identified increased risk of Down syndrome from a posi-
tive screening test (Leung et al. 2008).
For most women, when the indication for prenatal
diagnosis is AMA (in isolation or combined with mater-
nal serum and ultrasonographic screening for fetal (NT),
this risk is usually relatively low, in order of 0.1-0.2%
(Grimshaw et al. 2007). In other words, in the low risk
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around 99.9-99.8%. In contrast, once a structural abnor-
mality of the fetus has been diagnosed using ultrasonog-
raphy, the risk may be substantially increased. The risk
of fetal chromosome abnormality is increased when ei-
ther parent is a carrier of a chromosome rearrangement
such as translocation, inversion, or insertion. Neither FISH
nor QF-PCR aneuploidy assay are applicable. Either
karyotyping or specific molecular testing is mandatory
(Chen et al. 2001).
Our findings show that all clinically significant nu-
meric cytogenetic abnormalities (trisomy 21, trisomy 13,
and trisomy 18, and sex chromosome abnormalities) can
be detected if RAS was used as a stand-alone approach.
On the other hand, to carry out RAS FISH, amniocen-
tesis or CVS still needs to be performed. These invasive
techniques carry an intrinsic risk of miscarriage of 0.5%
and 1% respectively. With small as such risk may be, it
would seem prudent to have a thorough karyotype ana-
lysis to reveal the maximum information possible (Gekas
et al. 2011).
While the use of RAS to give a rapid result for the
common aneuploidies as adjunct to karyotyping is
recommended for routine prenatal diagnosis, this com-
bined approach clearly increases the cost of prenatal
diagnosis. However, the quality of life and anxiety mea-
surements show a significantly increased health status
after diagnosis with RAS, and RAS allows earlier deci-
sion making in cases where the fetus has a detected
chromosomal abnormality (Gekas et al. 2011).
In addition, a joint statement by the American College
of Medical genetics and the American society for Human
genetics reaffirmed that all RAS tests results must be
followed up with karyotyping reports indicated that 15-
30% of cytogenetic abnormality detected by karyotyping
would not be detected by RAS, but the number of these
cytogenetic abnormality with risk of adverse outcome
above background levels are much lower, and the rele-
vance of diagnosing them via DS screening programs is
debated owing their clinical significance (Lim et al. 2010).
On the other hand, the termination of pregnancy re-
mains a contentious issue in many societies, despite the
socially acceptable view of abortion as immoral; many
Muslims would personally accept prenatal testing tech-
nology and may opt for termination of pregnancy for
conditions perceived to be burdensome for the child
(Ahmad et al. 2013). While this may be acceptable to lit-
erate Muslims, much of the Muslim population depend
on the local Imams (Muslim leaders), most of whom are
strongly against termination of life (Salihu 1997).
The Egypt population has reached 91 million by the
end of August 2012, and with the increase in the aver-
age growth rate to reach 2, we expect to have an added
2850 DS birth every year. Considering suffering familymembers, it means that an average of 11,400 family
member suffering both social and psychological, espe-
cially with the very limited resources for handicapped
children.
In economically developed countries, life expectancy for
individuals with DS continues to rise, and significant, if
uneven, progress has been made in education provision
and employment prospects for those with an intellectual
disability (Glasson et al. 2002). In contrast, the limited
literature from economically developing countries tends
to characterize life for people with intellectual disability
and their families as burdensome and stigmatized (Ghai
2001). A large number of individuals cannot afford
medical insurance and make use of the free-of-charge
state sector medical services; nonetheless, the utilization
of these services is impeded by transport costs, bureau-
cracy and complex management patterns. Therefore, the
only public health measure available to reduce the inci-
dence of DS births is antenatal screening followed by inva-
sive prenatal genetic diagnosis and selective therapeutic
abortion of affected fetuses (Scott et al. 2013).
Conclusion
We demonstrate that AF FISH as a RAS test, can provide
a rapid and accurate clinical method for prenatal identifi-
cation of chromosome aneuploidies as a stand-alone test
or adjunctive to karyotyping according to the indication
for amniocentesis. Due to the development of maternal
serum markers and sensitivity of ultrasonic technology,
the indications for amniocentesis are changing in Egypt in
the high social class sector of the Egyptian population.
The proportion of pregnancies with advanced maternal
age has increased, and in the absence of proper antenatal
screening and subsequent termination it will lead to an in-
crease in the incidence of live births with DS. All pregnant
women should have proper ANC which includes prenatal
screening for chromosomal aneuploidies as a part of the
Egyptian National Health Service.
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